8-K: Merit Medical Acquires C2 CryoBalloon Technology

Merit Medical Systems, Inc. has signed a definitive asset purchase agreement to acquire the C2 CryoBalloon device and related technology from Pentax of America, Inc. for $22 million.

Summary

• Merit Medical Systems, Inc. has entered into a definitive asset purchase agreement with Pentax of America, Inc. to acquire the C2 CryoBalloon device and related technology.
• The total purchase consideration is $22 million, consisting of a $19 million cash payment at closing and potential contingent payments of up to $3 million based on meeting certain milestones.
• The transaction is expected to close during the fourth quarter of 2025.
• The acquired assets are projected to contribute approximately $1 million in revenue from November 1, 2025, through December 31, 2025.
• The acquisition is projected to dilute Merit's non-GAAP net income and non-GAAP earnings per share by approximately $0.4 million and $0.01, respectively, for the period of November 1 to December 31, 2025.
• The acquisition is projected to dilute Merit's GAAP net income and GAAP earnings per share by approximately $0.5 million and $0.01, respectively, for the period of November 1 to December 31, 2025.
• For the full year ending December 31, 2026, the acquisition is projected to contribute revenue in the range of approximately $6 million to $8 million.
• The acquisition is projected to dilute Merit's non-GAAP net income and non-GAAP earnings per share by approximately $1 million to $2 million, or $0.02 $0.03 per share, respectively, for the full year 2026.
• The acquisition is projected to dilute Merit's GAAP net income and GAAP earnings per share by approximately $2 million to $3 million, or $0.03 $0.05 per share, respectively, for the full year 2026.
• The acquisition is projected to be accretive to earnings thereafter (after 2026).
• Merit intends to integrate the C2 CryoBalloon business into its Endoscopy portfolio, complementing existing products and customer base.
• Merit plans to transfer product manufacturing to its facility in South Jordan, Utah, over the next few months.
• Some PENTAX employees currently engaged in the C2 CryoBalloon business are expected to join Merit.

Sentiment

Score: 7

Explanation: The acquisition is strategically positive, expanding Merit's Endoscopy portfolio and market presence in gastroenterology with an innovative device. However, it is projected to be dilutive to earnings in the short term (2025 and 2026) before becoming accretive, which introduces some near-term financial headwind.

Positives

• Expands the Endoscopy portfolio with an innovative C2 CryoBalloon device and related technology.
• Strengthens Merit's position in the multi-billion dollar gastroenterology market.
• Projected to add approximately $6 million to $8 million of revenue in 2026.
• Leverages Merit's existing commercial footprint in a key gastroenterology market.
• The C2 CryoBalloon treats serious conditions such as Barrett's esophagus and gastric antral vascular ectasia (GAVE) syndrome, enhancing patient care options.
• Expected to be accretive to earnings after 2026, indicating long-term financial benefit.
• Integration of PENTAX employees brings valuable knowledge and expertise to Merit.

Negatives

• Projected to be dilutive to non-GAAP net income and non-GAAP earnings per share by approximately $0.4 million and $0.01, respectively, for the period of November 1 to December 31, 2025.
• Projected to be dilutive to GAAP net income and GAAP earnings per share by approximately $0.5 million and $0.01, respectively, for the period of November 1 to December 31, 2025.
• Projected to be dilutive to non-GAAP net income and non-GAAP earnings per share by approximately $1 million to $2 million, or $0.02 $0.03 per share, respectively, for the full year 2026.
• Projected to be dilutive to GAAP net income and GAAP earnings per share by approximately $2 million to $3 million, or $0.03 $0.05 per share, respectively, for the full year 2026.
• A quantitative reconciliation of non-GAAP financial information to comparable GAAP financial information is not available without unreasonable effort.

Risks

• Inherent risks and uncertainties associated with the proposed acquisition of the C2 CryoBalloon device and related technology.
• Ability to integrate the acquired assets and operations and achieve projected financial results, product development, and other anticipated benefits of the proposed acquisition.
• Uncertainties as to whether Merit will achieve sales, gross and operating margin, net income, and earnings per share performance consistent with its forecasts projected for the acquired assets and operations.

Future Outlook

The acquisition is projected to contribute approximately $1 million in revenue from November 1 to December 31, 2025, and $6 million to $8 million in revenue for the full year 2026. It is expected to be dilutive to non-GAAP and GAAP net income and EPS in 2025 and 2026, becoming accretive thereafter. Merit plans to integrate the C2 CryoBalloon business into its Endoscopy portfolio and transfer manufacturing to its South Jordan, Utah facility.

Management Comments

• "We're excited to welcome new team members and expand our portfolio, empowering physicians to improve patient outcomes worldwide." Martha G. Aronson, Merit's President and CEO.
• "We believe this purchase will help our team optimize commercial activities in the multibillion-dollar gastroenterology market and provide physicians with more options to help care for their patients." Fred P. Lampropoulos, Merit's Chairman of the Board.
• "With its expanding footprint in upper gastrointestinal treatments and deep expertise in the field, Merit is ideally positioned to accelerate C2's growth, making it available to even more patients and clinicians worldwide." Dominique Vincent, President of PENTAX Medical.

Industry Context

This acquisition aligns with the broader trend in the medical device industry towards expanding specialized portfolios in high-growth therapeutic areas like gastroenterology. The focus on minimally invasive solutions for chronic conditions such as GERD and Barrett's esophagus reflects increasing demand for advanced, targeted treatments that improve patient outcomes and leverage existing commercial infrastructure.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results to global benchmarks.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through expanded market presence and accretive earnings post-2026, but short-term dilution in 2025 and 2026.
• Employees: Some PENTAX employees involved in the C2 CryoBalloon business are expected to join Merit, indicating potential new employment opportunities and integration challenges.
• Customers (Physicians/Hospitals): Expanded portfolio of minimally invasive solutions for gastrointestinal disorders, offering more options for treating conditions like Barrett's esophagus and GAVE syndrome.
• Patients: Access to innovative C2 CryoBalloon technology for improved outcomes in treating chronic gastroesophageal reflux disease (GERD) and other gastrointestinal tissue disorders.
• Suppliers: Potential changes in supply chain as manufacturing transfers to Merit's facility.

Next Steps

• Closing of the proposed transaction during the fourth quarter of 2025, subject to customary closing conditions.
• Integration of the C2 CryoBalloon business into Merit's Endoscopy portfolio.
• Transfer of product manufacturing to Merit's facility in South Jordan, Utah, over the next few months.
• Some PENTAX employees currently engaged in the C2 CryoBalloon business will be joining Merit.

Key Dates

Recommendation

The acquisition of the C2 CryoBalloon technology is a strategically sound move for Merit Medical, expanding its presence in the high-growth gastroenterology market with an innovative product. While the acquisition is projected to be dilutive to earnings in the short term (2025 and 2026), the long-term outlook is positive, with expected accretion thereafter and leveraging of existing commercial infrastructure. This move enhances Merit's product portfolio and addresses significant medical needs, positioning the company for sustained growth for long-term investors.

Keywords

Medical Devices, Gastroenterology, Endoscopy, Cryoablation, Barrett's Esophagus, Acquisition, Healthcare Technology, GERD, GAVE Syndrome